Cipla Backs Chase For Alzheimer’s Drug Research
This article was originally published in PharmAsia News
The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.
You may also be interested in...
Clinical trial results reported at AAIC demonstrate the variety of approaches, from novel to repurposed, in play as drugmakers attempt to delay the onset, slow the progression or even prevent the world’s second-most dreaded disease. It’s an arena in which first-in-human data can achieve rock star status.
Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research
MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.